

{PRIVATE }

## AMENDMENTS

### Amendments to the Claims

1. (Previously presented) A method for extending the effective period during which tissue treated with a clostridial toxin is paralyzed comprising:
  - a) contacting said tissue with a composition comprising an agent able to prevent the expression of a neurotrophic polypeptide, and
  - b) contacting said tissue with a clostridial neurotoxin,wherein neural sprouting in said treated tissue is inhibited.
2. (Previously presented) The method of claim 1 wherein step a) occurs at the same time as said tissue is treated with said clostridial toxin.
3. (Previously presented) The method of claim 1 wherein step a) occurs prior to treatment of said tissue with said clostridial toxin.
4. (Original) The method of claim 1 wherein said clostridial toxin comprises BoNT.
5. (Original) The method of claim 1 wherein said clostridial toxin comprises BoNT/A.
6. (Original) The method of claim 1 wherein said agent is selected from the group consisting of:
  - a) an antibody able to selectively bind said polypeptide,
  - b) a competitive inhibitor of said polypeptide,
  - c) a compound able to selectively prevent the expression of a gene encoding said polypeptide,

{PRIVATE }

- d) a binding protein other than an antibody, and
  - e) a ribozyme,
  - f) a nucleic acid encoding an inactive growth factor receptor able to bind said growth factor.
7. (Original) The method of claim 6 wherein said agent is an antibody able to selectively bind said polypeptide.
8. (Original) The method of claim 6 wherein said agent is a competitive inhibitor of said polypeptide.
9. (Original) The method of claim 6 wherein said agent is a compound able to prevent the expression of a gene encoding said polypeptide.
10. (Original) The method of claim 6 wherein said agent is a binding protein other than an antibody.
11. (Original) The method of claim 9 wherein said polypeptide is selected from the group consisting of IGF I and IGF II, and said binding protein is selected from the group consisting of IGF-BP4 and IGF-BP5.
12. (Original) A method for stimulating the outgrowth of neural sprouts from damaged neural tissue comprising: contacting said tissue with a composition comprising a polypeptide which comprises a neurotrophically active domain derived from an agent selected from the group consisting of IGF I, IGF II, ciliary neurotrophic factor, NT-3, NT-4, brain-derived neurotrophic factor, leukemia inhibitory factor, tenascin-C, ninjurin, neural cell adhesion molecule, and neural agrin.
13. (Currently amended) The method of ~~claim 11~~ claim 12 wherein said agent comprises

{PRIVATE}

IGF I.

14. (Currently amended) The method of ~~claim 11~~ claim 12 wherein said agent comprises IGF II.
15. (Currently amended) The method of ~~claim 11~~ claim 12 wherein said agent comprises NT-3.
16. (Currently amended) The method of ~~claim 11~~ claim 12 wherein said agent comprises ciliary neurotrophic factor.
17. (Currently amended) The method of ~~claim 11~~ claim 12 wherein said agent comprises NT-3.
18. (Currently amended) The method of ~~claim 11~~ claim 12 wherein said agent comprises NT-4.
19. (Currently amended) The method of ~~claim 11~~ claim 12 wherein said agent comprises brain-derived neurotrophic factor.
20. (Currently amended) The method of ~~claim 11~~ claim 12 wherein said agent comprises leukemia inhibitory factor.
21. (Currently amended) The method of ~~claim 11~~ claim 12 wherein said agent comprises tenascin-C.
22. (Currently amended) The method of ~~claim 11~~ claim 12 wherein said agent comprises ninjurin.
23. (Currently amended) The method of ~~claim 11~~ claim 12 wherein said agent comprises neural-cell adhesion molecule.

{PRIVATE }

24. (Currently amended) The method of ~~claim 14~~ claim 12 wherein said agent comprises neural agrin.

25. (Previously presented) The method of claim 1 wherein said polypeptide is selected from the group consisting of: IGF I, IGF II, ciliary neurotrophic factor, NT-3, NT-4, brain-derived neurotrophic factor, leukemia inhibitory factor, tenascin-C, ninjurin, neural cell adhesion molecule, and neural agrin.